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Multidrug efflux pumps adversely affect both the clin-
ical effectiveness of existing antibiotics and the
discovery process to find new ones. In this study,
we reconstituted and characterized by surface plas-
mon resonance the assembly of AcrAB-TolC, the
archetypal multidrug efflux pump from Escherichia
coli. We report that the periplasmic AcrA and the
outermembrane channel TolC assemble high-affinity
complexeswith AcrB transporter independently from
each other. Antibiotic novobiocin and MC-207,110
inhibitor bind to the immobilized AcrB but do not
affect interactions between components of the
complex. In contrast, DARPin inhibits interactions
between AcrA and AcrB. Mutational opening of
TolC channel decreases stability of interactions and
promotes disassembly of the complex. The confor-
mation of the membrane proximal domain of AcrA
is critical for the formation of AcrAB-TolC and could
be targeted for the development of new inhibitors.INTRODUCTION
Antimicrobial drug resistance is the leading challenge in the
management of infectious diseases (Levy and Marshall, 2004;
Talbot et al., 2006). Some pathogens have acquired resistance
to multiple antibiotics and cause infections that are effectively
untreatable. Among gram-negative pathogens, species have
emerged that are resistant to all good antibiotics (i.e., those
with few adverse effects), and many Enterobacteriaceae are
resistant to all antibiotics except carbapenems (Livermore,
2004). Thus, there is a strong need for new approaches to
combat multidrug-resistant gram-negative bacteria.
The high intrinsic and acquired antibiotic resistance of gram-
negative pathogens is believed to be a synergistic effect of the
active efflux of antibiotics from cells and their slow influx from
medium across the outer membrane (Zgurskaya and Nikaido,
2000). The synergy between these two counter-directed fluxes
is enabled by multidrug efflux pumps, such as AcrAB-TolC
from E. coli, which actively transport antibiotics from the peri-
plasm or cytoplasm directly into the external medium. The
homologs of AcrAB-TolC were identified in all gram-negative
pathogens and were implicated in high levels of antibiotic resis-
tance in various clinical isolates (Piddock, 2006).454 Chemistry & Biology 18, 454–463, April 22, 2011 ª2011 ElsevierThe assembly of AcrAB-TolC complex is a mechanistic as well
as a methodological conundrum, because two components of
the complex, the drug transporter AcrB and the outer membrane
channel TolC, are located in two different membranes separated
by a periplasm. Previous modeling and genetic studies sug-
gested that AcrAB-TolC complex is assembled into a large
protein conduit that spans both membranes of E. coli and the
periplasm (Bavro et al., 2008; Fernandez-Recio et al., 2004;
Husain et al., 2004; Mikolosko et al., 2006; Murakami et al.,
2002; Seeger et al., 2006; Symmons et al., 2009). In this complex,
the inner membrane transporter AcrB and the outer membrane
channel TolC form stable trimers extending deep into the peri-
plasm. The large periplasmic domains of AcrB and TolC meet
halfway across the periplasm and match each other in the size
and geometry, suggesting that these two proteins could interact
with each other. A direct interaction between AcrB and TolC was
supported by in vivo cysteine cross-linking studies and genetic
experiments (Tamura et al., 2005; Weeks et al., 2010).
The proposed interface between AcrB and TolC appears to be
limited to the apices of their periplasmic domains (Bavro et al.,
2008; Symmons et al., 2009). This observation prompted an
idea that AcrB-TolC complex is stabilized by the periplasmic
membrane fusion protein (MFP) AcrA. In crystals, AcrA has an
elongated modular structure that enables interactions with
both AcrB and TolC located in the inner and outer membranes,
respectively (Mikolosko et al., 2006). The cross-linking and
computer modeling studies suggested that three domains of
AcrA, namely lipoyl-binding, ab-barrel andmembrane proximal
(MP), interact with the periplasmic domain of AcrB, whereas its
a-helical hairpin binds TolC (Lobedanz et al., 2007; Symmons
et al., 2009). The bi-partite AcrA-AcrB and AcrA-TolC interac-
tions have been demonstrated in vitro (Tikhonova et al., 2009;
Tikhonova and Zgurskaya, 2004; Touze et al., 2004). However,
the reconstitution of the complete tri-partite complex has not
been achieved.
Because in E. coli the outer membrane component of the
complex is shared by multiple transporters, current models
postulate that TolC is engaged by a particular inner membrane
transporter only transiently (Zgurskaya, 2009). The periplasmic
MFPs, such as AcrA, are proposed to play an important role in
this process by trapping TolC into a complex. In agreement,
MFPs that function with various efflux pumpswere found to differ
in their affinities toward TolC, suggesting that the recruitment of
TolC into efflux complexes is under kinetic control (Tikhonova
et al., 2009). It remains unclear at what step during the complex
assembly TolC binds AcrB and whether this interaction affects
AcrA-TolC interactions. Furthermore, in the assembled complex,
TolC is believed to adopt an open conformation that promotesLtd All rights reserved
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C Figure 1. Immobilization of AcrB
(A) Purification and biotinylation of AcrBS1043C.
Purified AcrBS1043C (0.5 mg) and its biotinylated
derivative Cys1043bio were mixed with the SDS-
sample buffer plus/minus 10 mM DTT and sepa-
rated by 10% SDS-PAGE. Protein was either
stained with Coomassie Brilliant Blue (CBB) or
transferred onto PVDF membrane and incubated
with streptavidin alkaline phosphatase (anti-biotin).
Cys1043bio–anti-biotin complexwasvisualizedwith
nitro-blue tetrazolium chloride (NBT) and 5-bromo-
4-chloro-30-indolyphosphate p-toluidine (BCIP) salt
substrates.
(B) Fractionation of Cys1043bio by size exclusion
chromatography. Cys1043bio was injected onto
YM-Pack Diol-300 column at 0.5 ml/min in 20 mM
Tris-HCl (pH 7.5), 150 mM NaCl, and 0.03% DDM
(Tris buffer). Eluted fractions (0.25 ml) were
collected, of which B11 and B14 fractions were
used in SPR assays.
(C) Anti-biotin western analysis of Cys1043bio
(2.3 mM) treated with indicated concentrations of
the amine-reactive cross-linker dithiobis[succini-
midyl] propionate (DSP) in buffer containing 20mMHEPES-KOH (7.7), 150mMNaCl, and0.03%DDM.The reactionswere performed for 30minat 37C.Monomeric
AcrB and its cross-linked dimers and trimers are indicated.
(D) Kinetic analysis of DARPin binding to AcrB. Two-fold serial dilutions of DARPin (12.5–800 nM) in Tris buffer were injected over Cys1043bio (AcrB thereafter)
immobilizedatdensity2040RU (red lines).Datawerefitglobally toa1:1Langmuirmodel (black), givingk1=1.03310
6M1s1, k1=0.047s
1, leading toKD=46nM.
(E)DARPin interactionwithAcrB fractions.TheunfractionatedCys1043bio (B total) and itsB11andB14 fractionswere immobilizedatdensities2384RU,2348RUand
2414 RU, respectively. DARPin (100 nM) was injected at 50 ml/min for 2 min in running buffer containing 20mMMES-KOH (pH 6.0), 150mMNaCl, and 0.03%DDM
(MES buffer).
See also Table S1.
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Assembly of Multidrug Efflux Pump AcrAB-TolCdiffusion of drugs through the TolC channel into the medium.
Whether binding of AcrA or AcrB or both components triggers
this conformation transition in TolC is under debate.
In this study, we used a surface plasmon resonance approach
to investigate interactions between components of AcrAB-TolC
complex and a possible role of substrates and inhibitors in the
assembly of the complex. We report the reconstitution and anal-
ysis of all interactions within the AcrAB-TolC complex.RESULTS
Immobilization of AcrB
To immobilize AcrB on a surface in a specific orientation, we
constructed AcrB containing a single cysteine residue on its
C terminus. For this purpose, the two native cysteine residues
C493 and C887 of AcrB were replaced with serines (AcrBCL)
anda singleS1043Csubstitutionwas introducedby site-directed
mutagenesis (AcrBS1043C). When produced from plasmids along
with AcrA, both AcrBCL and AcrBS1043C complemented the drug-
susceptible phenotype of DacrAB cells, demonstrating that
mutations did not disrupt multidrug efflux activity (see Table S1
available online).
A biotin moiety was attached to the C1043 of purified
AcrBS1043C (Cys1043bio) using a thiol-reactive reagent biotin-
maleimide (Figure 1A). The light scattering coupled to size exclu-
sion HPLC (LS-SEC) showed that Cys1043bio is eluted from the
column as amajor peak (B14) preceded by a shoulder (B11) (Fig-
ure 1B). On the basis of the light-scatteringmeasurements, these
peaks correspond to AcrB dimers and trimers with molecular
masses 244 ± 7 and 379 ± 11 kDa, respectively. A minor peak
eluted the last from the column is likely composed of AcrBmono-Chemistry & Biology 18,mers. This result is consistent with previous reports (Stroebel
et al., 2007) that gel filtration separates AcrB into a heteroge-
neousmixture of quaternary structures. The chemical cross-link-
ing, however, showed that the predominant oligomeric form of
Cys1043bio is a trimer (Figure 1C). Thus, separation on the
column promotes dissociation of AcrB trimers.
A streptavidin-coated SA chipwas used to capture Cys1043bio
and its B11 and B14 fractions onto surface (AcrB thereafter). To
assess the binding capacity and the conformational state of im-
mobilized AcrB, we used inhibitor DARPin, which binds the peri-
plasmic domain of AcrB trimer with 2:3 stoichiometry and has
a strong preference to the Tight (T) and Loose (L) protomers of
AcrB (Sennhauser et al., 2007). In agreement with previous
studies, we found that DARPin binds AcrB with low nanomolar
affinity and follows a simple 1:1 Langmuir kinetics (Figure 1D).
The simple kinetics of DARPin binding implies that immobilized
AcrB is homogeneous. DARPin bound the B14 and B11 fractions
of AcrB with comparable efficiencies, suggesting that both these
fractions are immobilized in a structurally competent trimeric
form (Figure 1E). At saturation, the calculated stoichiometry of
DARPin:AcrBwasclose to 2:3,which is consistentwith the earlier
findings that two DARPin molecules bound per one asymmetric
AcrB trimer (Sennhauser et al., 2007).Immobilized AcrB Binds Substrates and Inhibitors
We tested several antibiotics, the known substrates of AcrB, for
their ability to bind the immobilized transporter. At pH 7.5, antibi-
otic novobiocin and the broad spectrum efflux pump inhibitor
MC-207,110 (Lomovskaya et al., 2001) produced strong binding
responses (Figures 2A and 2D). These analytes however, bound
AcrB surface with on and off rates, which are too fast for kinetic454–463, April 22, 2011 ª2011 Elsevier Ltd All rights reserved 455
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Figure 2. Binding of Inhibitors and
Substrates to Immobilized AcrB
(A) Sensorgrams of two-fold dilutions 12.5–200 mM
of MC-207,110 injected over AcrB surface (2040
RU) in Tris (pH 7.5) buffer.
(B) Scatchard plots of equilibrium binding
responses of MC-207,110 at pH 7.5 and pH 6.0.
Averages of three independent experiments are
shown. Error bars are standard deviations.
(C) Chemical structure of MC-207,110.
(D) Sensorgrams of two-fold dilutions 25–200 mM
of novobiocin (NOV) injected over AcrB surface
(2040 RU) in Tris (pH 7.5) buffer.
(E) Scatchard plot of equilibrium binding
responses of novobiocin at pH 7.5. Averages of
three independent experiments are shown. Error
bars are standard deviations.
(F) Chemical structure of novobiocin.
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Assembly of Multidrug Efflux Pump AcrAB-TolCmodeling. Analysis of the association equilibrium data showed
that binding of MC-207,110 and novobiocin to AcrB could be
reasonably well approximated by 1:1 binding kinetics with disso-
ciation equilibrium constants (KD) in the high micromolar range
(Figures 2B and 2E). Decreasing pH to 6.0 increased affinity of
MC-207,110 toward AcrB (Figure 2B). Novobiocin precipitated
from solution at pH 6.0 and its binding to AcrB could not be
studied at this pH.
We also tested other water-soluble substrates of AcrB,
including antibiotics oleandomycin, ampicillin, and cloxacillin.
No specific binding response was detected for these molecules
(data not shown). Perhaps the low affinity and small size of these
analytes precludes analysis of their binding to AcrB by SPR.
Lipidation of AcrA Is Essential for High-Affinity Binding
to AcrB
Previous structural and biochemical analyses of AcrA and AcrAB
complex were performed with the soluble variant of AcrA lacking
the N-terminal lipid modification (AcrAs) (Figure 3A) (Mikolosko
et al., 2006; Touze et al., 2004; Zgurskaya and Nikaido, 1999b).
When AcrAs was injected over AcrB surface, the binding
response was very low both at pH 7.5 and pH 6.0 (Figure 3B).
The injection of the native lipid-modified AcrA (AcrAl), however,
resulted in a strong binding response at pH 6.0 but not at pH 7.5.
Analysis of the two AcrA variants by LS-SEC showed that lipid
modification of AcrA promotes oligomerization. Consistent with
previous reports, AcrAs was eluted from the column as a single
symmetric peak with molecular weight 40 kDa at both pH 7.5
and 6.0 (Figure 3C). In contrast, the elution profile of AcrAl was
heterogeneous and depended on pH of the buffer (Figure 3D).
At pH 6.0, the molecular mass of AcrAl in the major peak was
found to be 100 ± 4 kDa, which corresponds to AcrA dimer. The
AcrAl dimer peak was preceded by a shoulder, which could
comprise an AcrAl conformer or a trimer. The increase of pH to
7.5 led toadramatic changeof theelutionprofilewith appearance
of large amounts of higher-order AcrAl oligomers (Figure 3D).
To determine which form of AcrAl has higher affinity to AcrB,
AcrAl-containing fractions eluted from the gel filtration column
at pH 6.0 were injected over immobilized AcrB and its B11 and456 Chemistry & Biology 18, 454–463, April 22, 2011 ª2011 ElsevierB14 fractions. On all three surfaces, the strong binding response
was obtained only for fractions containing dimeric AcrAl
(Figure 3E). Thus, the lipidation-dependent AcrAl dimerization
promotes high affinity binding to AcrB.
We next compared the proteolytic patterns of AcrAl and AcrAs
generated by trypsin digest to further investigate the effect of
lipidation and oligomerization on AcrA structure (Figure 3F).
Although both AcrA variants were cleaved into the same set of
fragments, the T47-K346 fragment of AcrAl was notably more
resistant to cleavage than the corresponding fragment of AcrAs.
This result suggested that AcrAl oligomerization leads to protec-
tionofR315 residue located in theMPdomainofAcrAl (Figure3A).
Previously, we found that G363C substitution in theMPdomain
of AcrAl (AcrAG363C) disrupts themultidrug efflux activity ofAcrAB-
TolC (Ge et al., 2009). To determine whether the MP domain is
indeed important for the AcrA-AcrB interaction, we purified
AcrAG363C and compared its properties to those of AcrAl and
AcrAs. In agreement with previous studies (Ge et al., 2009), cells
producing AcrAG363C were significantly more susceptible to
multipleantibiotics (TableS1). TheSECelutionprofileofAcrAG363C
matched that of AcrAl, demonstrating that this substitution does
not change the oligomeric state of AcrAl (Figure 3D). Accordingly,
the SDS-PAGE analysis under nonreducing conditions confirmed
thatAcrAG363C is adimer covalently linkedbyadisulfidebond (Fig-
ure 3G). The proteolytic pattern of AcrAG363C, however, was
distinct from both AcrAs and AcrAl (Figure 3F). The amounts of
T47-K346 fragment of AcrAG363Cwere similar to those in the AcrAl
pattern.At thesametime, theQ29-K374andT47-K396 fragments,
which were rapidly cleaved in both AcrAs and AcrAl, became the
major bands in the AcrAG363C pattern. This result suggests that
the G363C substitution changes the structure of the MP domain.
The SPR experiments further showed that the structural changes
causedbyG363Csubstitutionareunfavorable forAcrA interaction
with AcrB. The rate of association of AcrAG363C with immobilized
AcrB was visibly slower than that of AcrAl (Figure 3B).
Taken together, these results demonstrate that the N-terminal
lipidation promotes AcrA oligomerization and stabilizes its MP
domain.We further conclude that the structure of theMPdomain
is essential for the interaction between AcrA and AcrB.Ltd All rights reserved
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Figure 3. AcrA Lipidation Promotes Oligomerization and High-Affinity Binding to AcrB
(A) Graphical representation of AcrA structure with four domains and trypsin-accessible sites (Ge et al., 2009) indicated. C25, the site of lipid modification, and
G363 important for AcrA function are also shown.
(B) Sensorgrams of AcrA and its derivatives. AcrAl (1 mM, black), AcrAG363C (1 mM, red) and AcrAs (4 mM, violet) were injected over AcrB (2040 RU) in MES pH 6.0
(solid lines) and Tris pH 7.5 buffers (dashed lines).
(C) Size exclusion chromatography of AcrAs in MES buffer (solid line) and Tris buffer (dashed line).
(D) Size exclusion chromatography of AcrAl in MES pH 6.0 (solid black line) and Tris pH 7.5 (dashed black line) buffers and AcrAG363C in MES pH 6.0 (red line).
(E) AcrAl fractions (0.25 ml) eluted from YM-Pack Diol-300 column (280 nm, solid line) in MES buffer at 1.0 ml/min were injected over immobilized unfractionated
AcrB (B) and its B11 and B14 fractions (see Figure 1 for details). Normalized equilibrium binding responses of AcrAl fractions on each AcrB surface are plotted
against fraction number.
(F) Trypsin digestion patterns of AcrA variants. Proteins (2 mM) were digested with trypsin (0.1 mM) in MES buffer at 37C. Aliquots were taken at indicated times,
mixed with SDS-sample buffer and boiled. Digestion products were resolved on 12% SDS-PAGE and silver stained.
(G) 10% SDS-PAGE analysis of AcrAl and AcrAG363C under reducing and non-reducing conditions.
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To analyze kinetics of AcrA-AcrB interactions, increasing
concentrations of AcrAs, AcrAl, and AcrAG363C were injected
over AcrB surface at pH 6.0 (Figure 4 and Table 1). For AcrAs,
the data fit well to a simple 1:1 bindingmodel with the equilibrium
dissociation constant KD = 1.2 mM (Figure 4A). In contrast, the
quantitative analysis of the AcrAl and AcrAG363C curves showed
complex reactions (Figures 4B and 4C). The association and
dissociation phases could be best approximated using double-
exponential rate equations, indicating multiple reaction events.
The best fit of AcrAl-AcrB and AcrAG363C-AcrB binding curves
was obtained for the model that assumes conformational
change upon association (two-state reaction, TS). According to
this model, the initial association event (k1 in Table 1) was char-
acterized by themoderate rates104M1 s1 for both AcrA vari-
ants. However, association of AcrAG363C with AcrB was 44%
slower than that of AcrAl. Furthermore, G363C substitution led
to about two-fold increase in the off-rates for both steps
indicating the decreased stability of AcrA-AcrB complex. The
KD = 0.23 mMand KD = 0.09 mM for AcrA
G363C and AcrAl, respec-
tively, were at least 5–10-fold higher than the KD of AcrA
s.
To investigate possible effects of substrates and inhibitors on
AcrA-AcrB interactions, we mixed AcrAl and inhibitors inChemistry & Biology 18,different molar ratios and injected them over the immobilized
AcrB. We found no significant effect on AcrA-AcrB interactions
by antibiotics oleandomycin and novobiocin and inhibitor
MC-207,110 at up to 100 molar excess of drug over AcrA
(Figure 4D). In contrast, increasing concentrations of DARPin
significantly inhibited binding of AcrAl to AcrB (Figure 4E). Even
at submolar DARPin:AcrAl ratios, the AcrAl binding response
decreased up to 80%. Because no interaction between DARPin
and AcrAl was detected (data not shown), we conclude that
binding of DARPin to AcrB interferes with the assembly of
AcrAl-AcrB complex.
TolC Binds AcrB Independently from AcrA
Structural and genetic studies suggested that TolC could directly
interact with AcrB, but the extent and timing of such interaction is
unclear (Bavro et al., 2008; Tamura et al., 2005). To investigate
AcrB-TolC interaction, the increasing concentrations of purified
TolC were injected over AcrB surfaces at pH 6.0 and 7.5 (Figures
5A and 5B). At both pH levels, TolC interacted specifically with
AcrB but at the same concentrations TolC binding signal at pH
6.0 was more than ten times higher than at pH 7.5. TolC inter-
acted with AcrB surface, which was never exposed to AcrA,
excluding the possibility that traces of AcrA on the AcrB surface454–463, April 22, 2011 ª2011 Elsevier Ltd All rights reserved 457
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Interactions
(A–C) Two-fold serial dilutions of 1.0–4.0 mMAcrAs
(A), 0.0625–1.0 mM AcrAl (B), and 0.0625–1.0 mM
AcrAG363C (C) in MES buffer were injected onto
AcrB (2040 RU). Sensorgrams (red lines) are fit
globally using the TS model (black lines).
(D) AcrAl (1.0 mM) in Tris buffer was premixed with
increasing concentrations of MC-207,110 (open
square), NOV (black diamond), or in MES buffer
with oleandomycin (red triangle), incubated at
room temperature and injected over AcrB. The
normalized sensorgram of AcrAl (1.0 mM) alone
was subtracted from the sensorgrams of AcrAl
plus inhibitor mixtures. AcrAl bound in the pres-
ence of drug at equilibrium (6 s before dissociation)
was expressed as a percentage of the AcrAl
bound drug-free and plotted as a function of
a molar drug/AcrA ratio. Averages of three inde-
pendent experiments and standard deviations are
shown.
(E) AcrAl (1.0 mM) or DARPin (0.05 mM) in MES
buffer were mixed with increasing concentrations
of DARPin or AcrAl,s respectively, and injected onto AcrB surface (3222 RU). Data were normalized as described in (D). Percentages of bound DARPin (squares)
and AcrAl (circles) in the corresponding mixtures at equilibrium are plotted as functions of DARPin/AcrA molar ratios in mixtures.
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Assembly of Multidrug Efflux Pump AcrAB-TolCare responsible for the observed TolC-AcrB interaction. Binding
of TolC to AcrB was insensitive to the presence of oleandomycin
but decreased by 30%–40% in the presence of novobiocin and
MC-207,110 (Figure 5C).
The best fit of AcrB-TolC curves was also obtained for the TS
model (Figure 5B). On the basis of this model, the initial associa-
tion with AcrB was significantly faster for TolC than for AcrAl
(Table 1). However, the slower conformational transition steps
were similar for the two proteins. The equilibrium dissociation
constant for TolC-AcrB complex derived from the rates shown
in Table 1 (KD 0.09 mM) was similar to that for AcrAl-AcrB
complex. Thus, TolCbindsAcrBdirectly andwith the high affinity.
Mutational Opening of the TolC Channel Decreases
Its Affinity Toward AcrA and AcrB
Structural and modeling studies suggested that the best fit
between TolC and AcrB is achieved when TolC is modeled in
its proposed open conformation (Bavro et al., 2008; Symmons
et al., 2009). We next constructed TolC mutant containing
Y362F and R367E substitutions in its periplasmic domainTable 1. Kinetic Parameters of AcrB-AcrA and AcrB-TolC Interactio
Analyte, mM pH k1, M
1 s1 k1, s1
AcrAs, 0.5–4.00a 7.5 (1.33 ± 0.22) 3 104 (3.85 ± 0.26) 3 1
AcrAs, 1.0–4.00a 6.0 (6.9 ± 0.09) 3 103 (8.09 ± 0.31) 3 1
AcrAl, 0.5–8.00a 7.5 (4.73 ± 0.04) 3 103 (2.91 ± 0.06) 3 1
AcrAl, 0.06–1.00b 6.0 (2.39 ± 0.06) 3 104 (2.1 ± 0.14) 3 1
AcrAG363C, 0.06–2.00b 6.0 (1.35 ± 0.09) 3 104 (3.76 ± 0.6) 3 10
TolC, 0.125–1.0a 7.5 (4.1 ± 0.27) 3 104 (3.15 ± 0.09) 3 1
TolC, 0.03–0.5b 6.0 (8.94 ± 0.19) 3 104 (4.17 ± 0.16) 3 1
TolCYFRE, 0.03–0.5b 6.0 (5.46 ± 0.03) 3 104 (4.8 ± 0.004) 3
a Data were fit globally using the 1:1 Langmuir binding model.
b Data were fit globally using the TS model. k-1, k-2, k1, and k2 are microscop
from the ratio of the dissociation and association rate constants. Numbers sh
RU) and on the same day.
458 Chemistry & Biology 18, 454–463, April 22, 2011 ª2011 Elsevier(TolCYFRE). These mutations destabilize the critical salt bridges
in the periplasmic entrance of TolC and trigger partial opening
of the channel (Andersen et al., 2002; Bavro et al., 2008). In
agreement with previous studies, TolCYFRE protected E. coli,
albeit only partially, from various antimicrobials, indicating that
thismutant is assembled into themultidrug efflux complex (Table
S1). TolCYFRE was then purified and compared to the wild-type
protein in binding to immobilized AcrA and AcrB.
To characterize AcrA-TolCYFRE interactions, we used
AcrAS362C mutant with a single cysteine substitution in the posi-
tion 362, which, in contrast to AcrAG363C, is fully functional in
multidrug efflux (Ge et al., 2009). For immobilization, AcrAS362C
was modified with biotin-maleimide and captured onto the SA
chip under the same conditions as AcrB. TolCYFRE was next in-
jected either over AcrA or AcrB surface, and its binding affinity
was compared to that of the wild-type TolC. The mutational
opening of TolCYFRE significantly affected its interactions with
both AcrA and AcrB proteins (Figures 5D and 5E).
In agreement with the previous studies (Tikhonova et al.,
2009), the best fit for AcrA-TolC binding was obtained for thens
k2, M
1 s1 k2, s
1 KD, mM
02 — — 2.89
03 — — 1.17
03 — — 0.67
0–2 (1.21 ± 0.08) 3 10–2 (1.11 ± 0.26) 3 10–3 0.09
–2 (2.9 ± 0.2) 3 10–2 (2.42 ± 0.18) 3 10–3 0.23
02 - - 0.77
0–2 (1.27 ± 0.04) 3 10–2 (2.41 ± 0.14) 3 10–3 0.09
10–3 (1.06 ± 0.002) 3 10–2 (1.16 ± 0.002) 3 10–3 0.10
ic rate constants. Equilibrium dissociation constants (KD) were calculated
own in bold are for the data sets collected on the sameAcrB surface (2040
Ltd All rights reserved
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Figure 5. Kinetic Analysis of TolC-AcrB Interactions
(A) Two-fold serial dilutions of TolC (0.03125–0.5 mM) in Tris buffer were injected onto AcrB (2040 RU). Sensorgrams (red lines) are fit globally using the
1:1 Langmuir binding (black lines).
(B) The same as (A) but experiments were performed in MES buffer. Data (red lines) were fit globally using the TS model (black lines).
(C) TolC (1.0 mM) in Tris buffer was premixed with increasing concentrations of MC-207,110 (open squares) and NOV (black diamond), whereas 0.125 mMTolC in
MES buffer was pre-mixed with oleandomycin (red triangle), incubated at room temperature and injected over AcrB. Equilibrium binding responses of TolC in the
presence of a drug were expressed as percentages of TolC bound in the absence of drugs and plotted as functions of a molar drug/TolC ratio.
(D) TolC and its open TolCYFRE variant (0.25 mM each) in MES buffer were injected over AcrAG362C (2081 RU) surface.
(E) The same proteins as in (D) injected over AcrB (2040 RU) surface.
(F) Two-fold serial dilutions of TolCYFRE (0.03125–0.5 mM) in MES buffer were injected over AcrB (2040 RU). Sensorgrams (red lines) are fit globally using the
TS model (black lines).
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Assembly of Multidrug Efflux Pump AcrAB-TolCmodel that assumed the presence of two populations of ligand
on the surface with fast and slow dissociation rates. On the basis
of this model, the affinities of TolC to two populations of AcrA
were KD1 = 0.01 mM and KD2 = 0.11 mM for the slow and fast
complexes, respectively. The rate and equilibrium constants
derived from the kinetic analysis of TolCYFRE interaction with
AcrA showed the notably lower affinity with KD1 = 0.02 mM and
KD2 = 6.7 mM for the slow and fast complexes, respectively.
As with TolC, binding of TolCYFRE to AcrB fit best to the TS
model (Figure 5F). The initial association, k1, and the second
dissociation, k-2 rates for TolC
YFRE were two times slower than
the corresponding rates for the wild-type protein. However, the
equilibrium dissociation constants, KD 0.1 mM, were very
similar for TolC-AcrB and TolCYFRE-AcrB complexes (Table 1).
This result shows that the conformation of the periplasmic tip
of TolC affects the rates of binding without changing the equilib-
rium of the reaction.
Mutations in the periplasmic entrance of TolCYFRE move the
three pairs of coiled coils radially outward from the central
molecular axis (Bavro et al., 2008). The greatest conformational
changes occur in the H7/H8 helices and lead to the widening
of the entrance and deepening of the proposed AcrA binding
grooves. If in solution TolCYFRE retains the same conformation,
our data suggest that this conformation is unfavorable for bothChemistry & Biology 18,TolC-AcrB and TolC-AcrA interactions and could promote faster
dissociation of AcrAB-TolC complex. The decreased affinity of
TolCYFRE to AcrAB is consistent with the partial activity of
TolCYFRE in multidrug efflux (Table 1).
Sequential Assembly of AcrAB-TolC Complex
The experiments described above established that TolC binds
both AcrA and AcrB with affinities in the nanomolar range. To
study the assembly of the three-component AcrAB-TolC
complex, AcrAl and TolC were premixed together at different
molar ratios and injected over the AcrB surface (Figure 6A). Using
this approach, we found no evidence for the formation of AcrAB-
TolC complex. Furthermore, even at submolar ratios, TolC in-
hibited assembly of AcrA-AcrB complexes, possibly because
TolC binding to AcrA in solution interfered with AcrA-AcrB inter-
actions on the surface (Figure 6A).
We next used a sequential coinjection approach to separate in
time the bi-partite interactions leading to the assembly of AcrAB-
TolC complex (Figures 6B–6E). In these experiments, AcrA-AcrB
or TolC-AcrB complexes are assembled during the first injection
and then are exposed to the respective third component in the
second injection. If the tri-partite complex is assembled on the
surface, then the second injection is expected to increase
the amounts of AcrA or TolC bound to AcrB. As shown on454–463, April 22, 2011 ª2011 Elsevier Ltd All rights reserved 459
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Figure 6. Reconstitution of AcrAB-TolC
(A) TolC versus AcrA competition experiment. AcrAl (0.5 mM) and TolC (0.03 mM) in MES buffer were mixed with increasing concentrations of a corresponding
competing analyte, incubated at room temperature, and injected over AcrB (2040 RU). The equilibrium binding responses of AcrA (circles) and TolC (triangles)
were expressed as percentages of the bound AcrA or TolC injected alone and plotted as functions of TolC:AcrA molar ratios.
(B–E) To reconstitute tri-partite complexes, TolC (B andC) or TolCYFRE (D and E) in concentration 0.125 mMwere injected alone onto AcrB (2040 RU) (I-1). Then the
same concentrations of TolC variants were premixed with either AcrAl or AcrAG363C at AcrA:TolC molar ratio 8:1 and injected onto AcrB (I-2) without dissociation
of the preassembled TolC-AcrB complexes (black solid lines). Dissociation was triggered by injecting buffer solution (I-3). The difference between normalized
coinjection sensorgrams and normalized AcrA/AcrAG363C sensorgrams are shown by blue solid lines with the assembled tri-partite complexes indicated by
shaded areas. Single analyte injections of TolC/TolCYFRE and AcrA/AcrAG363C are shown by dashed blue and black lines, respectively.
(F) The proposed model AcrAB-TolC assembly. Bi-partite AcrA-TolC, AcrA-AcrB and TolC-AcrB complexes are assembled with the same nanomolar affinities.
The assembly of the tri-partite complex however requires a conformational change in the MP domain of AcrA (black squares). The opening of TolC channel
decreases affinities to both AcrA and AcrB and leads to disassembly of the complex and TolC closing. OM, outer membrane; PG, peptidoglycan; IM, inner
membrane; MP, membrane proximal domain.
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Assembly of Multidrug Efflux Pump AcrAB-TolCFigure 6B, the preassembly of TolC-AcrB complexes on the
surface followed by injection of AcrA increased the amounts of
bound TolC, suggesting that the three-component complex is
assembled but its amounts are low (shaded area, Figure 6B).
Surprisingly, replacement of AcrA in the above reactions with
its AcrAG363C variant led to a notable 20% increase in the
amounts of the retained TolC and, correspondingly, AcrAB-
TolC complexes (shaded area, Figure 6C). Thus, the conforma-
tional change induced byG363C substitution in AcrA is favorable
for the tri-partite interactions. The assembly of the tri-partite
complex was also seen when AcrA-AcrB complex was preas-
sembled first, followed by the injection of TolC (data not shown).
The inclusion of oleandomycin into binding reactions did not
affect the assembly of the complexes.460 Chemistry & Biology 18, 454–463, April 22, 2011 ª2011 ElsevierWhen TolC was substituted with its open variant TolCYFRE, we
found no evidence of tri-partite interactions (Figures 6D and 6E).
This result strongly suggests that AcrAB-TolC complex is
assembled with the closed conformer of TolC.
Taken together, these results provide a strong experimental
evidence for the independent assembly of TolC-AcrB and
AcrA-AcrB complexes (Figure 6F). However, the preassembly
of AcrA-TolC in solution interferes with AcrA binding to AcrB,
indicating a sequential mechanism of the assembly. The
complete three-component AcrAB-TolC complex is favored
with AcrAG363C variant. Because G363C substitution affects
the AcrA MP domain, we conclude that the conformation of
this domain is important not only for AcrA-AcrB interactions
but also for the assembly of AcrAB-TolC.Ltd All rights reserved
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Extensive in vivo and in vitro studies yielded amodel of the three-
component AcrAB-TolC complex (Koronakis et al., 2000; Lobe-
danz et al., 2007; Mikolosko et al., 2006; Seeger et al., 2006).
However, how this complex is assembled remains unclear. In
this study, we succeeded in reconstitution of the bi-partite
AcrA-AcrB and TolC-AcrB and the full AcrAB-TolC complexes
and characterized kinetics of these interactions. Our data
suggest that AcrA-AcrB and TolC-AcrB complexes are formed
independently and that conformation of the MP domain of
AcrA is critical for the assembly of the tri-partite complex.
In this study, we addressed three highly debatable questions
about the assembly of AcrAB-TolC pump. The first question is
about the oligomeric state of AcrA. All MFPs are prone to oligo-
merization, albeit to a different degree andwith different affinities
(Tikhonova et al., 2009). Several indirect findings indicated that
MFPs associated with RND-type pumps, such as AcrA, might
bind a transporter in their dimeric forms (Bavro et al., 2008;
Fernandez-Recio et al., 2004; Misra and Bavro, 2009; Zgurskaya
et al., 2009). However, the chemical cross-linking in vivo and
structural modeling experiments of AcrAB-TolC suggested that
AcrA is a monomer when bound to AcrB (Symmons et al.,
2009). Our data provide a strong support for the model, in which
a dimeric AcrA binds an AcrB protomer establishing the stoichi-
ometry of AcrA-AcrB complex at 6:3. First, the affinity of AcrAl to
AcrB is by an order of magnitude higher than that of the soluble
variant (Figure 4). Our results show that this increase in affinity is
due to stabilization of the MP domain and AcrAl oligomerization
(Figure 3). Second, AcrAG363C is a dimer covalently linked by a di-
sulfide bond (Figure 3G). Yet this mutant bound AcrB with affinity
comparable to that of AcrAl, excluding the possibility that AcrA
monomerization is needed for complex formation. Finally,
DARPin inhibits binding of AcrAl (Figure 4E). In the crystal struc-
ture of AcrB-DARPin complex (Sennhauser et al., 2007), DARPin
occupies only one of the two putative AcrA-binding sites of AcrB.
Therefore, the inhibitory effect of DARPin is consistent with two
AcrA molecules bound per AcrB protomer. However, alternative
explanations such as the inhibitory effect of DARPin on confor-
mation of AcrB cannot be excluded at this point. Taken together,
these results strongly support the notion that AcrA dimers asso-
ciate with AcrB (Figure 6F).
The second question is howTolC is assembled into a complex.
Although it is broadly believed that AcrA is needed to engage
TolC into the complex (Koronakis et al., 2004; Nikaido and Takat-
suka, 2009; Pos, 2009; Zgurskaya, 2009), our results strongly
suggest that TolC interaction with AcrB is independent from
AcrA. The equilibrium dissociation constants for AcrA-AcrB
and TolC-AcrB complexes are in the same nanomolar range
(Table 1). However, the initial association rate for the TolC-
AcrB complex is at least four-fold faster than for AcrA-AcrB
complex, indicating that TolC-AcrB interactions are more
dynamic than those in AcrA-AcrB complex. Previously, the
TolC-AcrB complex was proposed on the basis of complemen-
tary distributions of charges in the periplasmic tips of TolC and
AcrB and on in vivo disulfide cross-linking of cysteine residues
positioned in the putative contacting loops of the two proteins
(Bavro et al., 2008; Tamura et al., 2005). Our experiments provide
a first biochemical evidence of TolC-AcrB complex and furtherChemistry & Biology 18,demonstrate that this complex is formed even in the absence
of AcrA. We propose that AcrA and TolC bind AcrB indepen-
dently and that the tri-partite complex is assembled between
AcrA and TolC bound to AcrB (Figure 6F).
Finally, the AcrAB-TolC model guided by in vivo cross-linking
data could only be assembled by altering the conformations of
both AcrA and TolC (Symmons et al., 2009). The proposed struc-
ture involves the forced opening of the periplasmic entrance of
TolC channel, which leads to the close fit between the apex of
the tip of TolC and AcrB and deepening of the intraprotomer
groove between the H3/H4 andH7/H8 helices of TolC. This intra-
protomer groove is proposed to be a high-affinity site for AcrA
needed for stabilization of the open conformation of TolC (Bavro
et al., 2008). We found, however, that the partial opening of TolC
by removing the critical salt bridges in the tip of TolC is unfavor-
able and leads to destabilization of both TolC-AcrB and TolC-
AcrA complexes, with the most profound effect on TolC-AcrA
(Figure 5). Furthermore, we found no evidence for the tri-partite
complex assembled with TolCYFRE (Figure 6). This result
suggests that, instead of stabilization, TolC opening could lead
to disassembly of AcrAB-TolC (Figure 6F). However, we cannot
exclude the possibility that the conformation of TolCYFRE does
not approximate the ‘‘true’’ open conformation of TolC and its
structural asymmetry is the reason for the lower affinity toward
AcrA (Bavro et al., 2008; Pei et al., 2011).
The assembly of the tri-partite AcrAB-TolC complex is most
evident with AcrAG363C mutant, in which the conformation of
the MP domain differs from that of the wild-type protein (Fig-
ure 6C). The proposed AcrA-AcrB interface is quite extensive
and involves three of the four domains of AcrA: the lipoyl, the
b-barrel, and the MP (Symmons et al., 2009). The limited prote-
olysis experiments showed that themajor changes in AcrA struc-
ture caused by G363C substitution are localized to the MP
domain (Figure 3F). Because the AcrA structure is very dynamic
and allows significant interdomain flexibility (Ip et al., 2003;Miko-
losko et al., 2006), it is possible that the conformation of the MP
domain is important for AcrA to engage into a tri-partite associ-
ation with AcrB and TolC. Perhaps in vivo or in membranes,
binding to AcrB is sufficient to trigger conformational changes
in AcrA needed for a complex formation. In detergents, however,
such conformation was promoted by G363C substitution in the
AcrA MP domain. We propose that in AcrAG363C-AcrB complex,
the orientation of AcrA is such that the a-helical hairpin can reach
and bind TolC already engaged into a complex with AcrB (Fig-
ure 6F). Importantly, open TolCYFRE mutant does not engage
AcrAG363C (Figure 6E).
The interactions between components of the AcrAB-TolC
complex were not stimulated by the presence of substrates and
even were slightly inhibited by novobiocin and MC-207,110.
Furthermore, among various compounds, only bindingof novobi-
ocin andMC-207,110 to AcrB could be detected and reproduced
consistently. Small molecule binding is often difficult to detect in
SPR assays because of the low signal. In contrast, novobiocin
andMC-207,110 binding responses on AcrB surface were unex-
pectedly high, suggesting either multiple binding sites or under-
estimation of their effective masses (Figure 2). It is possible that
the largesignal of thesecompounds is causedby formationof ho-
motypic aggregates or mixed detergent-inhibitor micelles.
Finally, the periplasmic concentrations of AcrA and TolC are454–463, April 22, 2011 ª2011 Elsevier Ltd All rights reserved 461
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Assembly of Multidrug Efflux Pump AcrAB-TolCestimated to be 100 and 3 mM, respectively (Tikhonova and
Zgurskaya, 2004). These concentrations arewell above the nano-
molar KDs for interactions between components of the complex
(Table 1) and imply that in vivo AcrB exists in the complex with
AcrA and TolC. Therefore, inhibitors with high micromolar activi-
ties are unlikely to act by inhibiting the interactions between
components of AcrAB-TolC complex.
SIGNIFICANCE
We describe the reconstitution of multidrug efflux pump
AcrAB-TolC that functions in the context of two membranes
of E. coli. Our results show that the tri-partite complex is
assembled between AcrA and TolC bound to AcrB with
high affinities. The likely stoichiometry of AcrA:AcrB:TolC
is 6:3:3. Antibiotics and MC-207,110 inhibitor do not modu-
late interactions between components of the complex. The
inhibitory effect of DAPRin on AcrAB-TolC function is due
to inhibition of AcrA-AcrB interactions. We report biochem-
ical assays that could be readily adapted for screening of
novel inhibitors that interfere with AcrAB-TolC assembly
and potentiate diverse antimicrobial agents. The conforma-
tional change in the MP domain of AcrA appears to be
a ‘‘bottleneck’’ in the assembly of the tri-partite complex
and could be targeted for development of effective inhibitors
of AcrAB-TolC assembly.
EXPERIMENTAL PROCEDURES
Purification of Proteins
Construction and purification of AcrAl, AcrAG362C, AcrAG363C, AcrAs, and TolC
containing the C-terminal six histidine (6His) affinity tags were reported before
(Ge et al., 2009; Tikhonova et al., 2009; Zgurskaya and Nikaido, 1999a). AcrAs
lacking the signal peptide and C25, the site of lipid modification, was overpro-
duced in and purified from the cytoplasm (Zgurskaya and Nikaido, 1999a). The
native AcrAl was purified from themembrane fraction (Ge et al., 2009). Plasmid
producing a cysteine-less AcrB variant and the purified DARPin (MW =
18.2 kDa) were a gift from Dr. Olga Lomovskaya. All other mutants were con-
structed using QuickChange site-directed mutagenesis kit (Stratagene).
AcrBS1043C without an affinity tag was purified using Cu2+ affinity chromatog-
raphy, as described previously (Zgurskaya and Nikaido, 1999b). Protein
concentrations were determined using the Protein DC assay (Bio-Rad) and
bovine serum albumin as a standard.
Light Scattering and Size Exclusion Chromatography (LS/SEC)
Proteins were analyzed by HPLC (Shimadzu) using YMC-Pack Diol-300 size
exclusion column. Protein samples (0.4–1.2 mg/ml) were injected in the buffer
containing 20 mM MES-KOH (pH 6.0), 0.03% dodecyl maltoside (DDM), and
150 mM NaCl (MES buffer) at the flow rate of 0.5 or 1.0 ml/min. For pH 7.5,
MES-KOH was substituted with 20 mM Tris-HCl (Tris buffer). The light scat-
tering (LS) and refraction index (RI) of eluted proteins was measured using
PD2010 light scattering detector (Precision Detectors, MA) and Waters 2414
detector, respectively. The molecular mass of the proteins was calculated
from the LS and RI data using Discovery software (Precision Detectors, MA)
as described earlier (Petrushenko et al., 2006).
Surface Plasmon Resonance
A BIAcore 3000 biosensor system was used to characterize binding interac-
tions. Disulfide bonds of purified AcrBS1043C and AcrAS362C were reduced
using Tris[2-carboxyethyl]phosphine hydrochloride disulfide reducing gel
(Pierce) in buffer containing 20 mM Tris-HCl (pH 7.0), 500 mM NaCl, 5 mM
EDTA, and when needed, 0.03% DDM. Biotinylation of AcrBS1043C and
AcrAS362C was performed with maleimide-PEG2-Biotin (Pierce) at 1:20 pro-
tein:biotin molar ratio in the same buffer for 2 hr on ice. Unreacted biotin-mal-462 Chemistry & Biology 18, 454–463, April 22, 2011 ª2011 Elseviereimide was removed from proteins by gel filtration on a NAP-5 column (GE
Healthcare) followed by overnight dialysis against 20 mM Tris-HCl (pH 7.5),
500 mM NaCl, and 0.03% DDM. Biotinylation was confirmed by separating
1.0 mg of a biotinylated protein on 10% SDS-PA gel followed by blotting
onto a PVDF membrane. The membrane was then treated with streptavidin-
alkaline phosphatase conjugate (Sigma) and a biotinyl-protein conjugate visu-
alized with NBT/BCIP reagents (Bio-Rad).
Biotinylated proteins were immobilized onto SA biosensor chip (Biacore) in
Tris buffer. Surface activation and coupling procedures were performed as
recommended by the manufacturer (GE Healthcare). To develop an SPR-
based binding assay, Cys1043bio was coupled to a SA biosensor chip surface
to various densities. A coupling density of 2,000 Response Units (RU) corre-
sponds to 2 ng/mm2 or 1000 AcrB molecules/mm2. This translates into the
concentration of immobilized AcrB 180 mM. For comparison, E. coli cells
contain approximately 500 copies of AcrB per cell (Tikhonova and Zgurskaya,
2004). If modeled as an ellipsoid with the surface area 2.4 mm2, an E. coli cell
contains 200 AcrB molecules/mm2 of the inner membrane.
As a control, we used an untreated SA surface. All experiments were per-
formed in MES buffer (pH 6.0) or Tris buffer (pH 7.5). Analytes (proteins, inhib-
itors and substrates) were diluted in running buffers. Between each analyte
injection, the surface was regenerated by brief injection of 40 mM CHAPS
prepared in 20 mM Tris-HCl (pH 8.0), 150 mM NaCl, and 0.03% DDM. For
reproducibility purposes, all injections were done in repetitions and on different
surfaces. To minimize mass transfer effects, the flow rate of injections was
kept at 50 ml/min. All shown sensorgrams are normalized by subtracting
responses from the control AcrB-free surface.Kinetic Analysis of TolC-AcrB and AcrA-AcrB Interactions
Datawere analyzedwith BiaEvaluation version 6 andMicrosoft Excel software.
At pH 6.0, both the association and dissociation phases of TolC-AcrB and
AcrA-AcrB SPR sensorgrams could be approximated as double exponential
decays. Such kinetics rules out simple reaction mechanisms and predicts at
least two distinct events during both protein binding and dissociation. The
best global fit for both AcrA-AcrB and TolC-AcrB was obtained using the
two-state reaction (TS) model. Schematic representation and equations rele-
vant to this model are given below:
A+B4A  B4½A  B; (1)
vðA  BÞ
vt
= k1½A½B  ðk1½A  B  k2½A  BÞ; (2)
vðA  BÞ
vt
= k2½A  B  k2½A  B; (3)
and Rt = ½A  B+ ½A  B: (4)
The equilibrium dissociation constant for this model is:
KD =
k1k2
k1k2
; (5)
where [A] is the concentration of analyte; [B] is the ligand binding capacity;
[A$B] and [A$B*] are intermediate and final complexes, respectively; k-1, k-2,
k1, and k2 are microscopic rate constants; and Rt is the total SPR response,
which is directly proportional to [A$B] + [A$B*].SUPPLEMENTAL INFORMATION
Supplemental Information includes one table and can be found with this article
online at doi:10.1016/j.chembiol.2011.02.011.ACKNOWLEDGMENTS
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